Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Randolph Noelle
Dartmouth College, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
ImmuNext, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
ImmuNext is developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. ImmuNext's lead program is based on VISTA, a novel checkpoint regulator in the B7 family and the subject of this research project. This NIH-funded project explores the mechanisms by which VISTA impacts on the action of the immune system, and therefore the information gained through this research will be of interest and value to ImmuNext.
The Conflict of Interest Committee determined that, given Dr. Noelle's role as PI in this project, his financial interest in ImmuNext (equity and consulting income as described above) could significantly and directly affect the design, conduct, and reporting of the research. Note also that Dr. Noelle received royalties in connection with intellectual property developed at Dartmouth which has been licensed to ImmuNext, Inc. through the awardee institution (which is not an SFI under the regulations but is an SFI under the Dartmouth College COI Policy), which have been included in this report (as described above).
VISTA, a novel regulator of immunity and autoimmunity
Checkpoint regulators represent a class of molecules that exert profound impact on the development of immunity. We have defined a new checkpoint regulator whose activity has been shown to impact on the development of immunity, autoimmunity and cancer. Already, fully humanahuman monoclonal antibodies are being produced for planned clinical trials. The basic immunology presented in this application is critica for sound therapeutic development of VISTA and VISTA agonists. This new molecule will be an important new target in the treatment of a wide range of immune-related diseases.
Filed on May 17, 2013.
Tell us what you know about Randolph Noelle's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Randolph Noelle filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Randolph Noelle | Dartmouth College | Conflict of Interest | ImmuNext, Inc. | >$600,000 |
| Randolph Noelle | Dartmouth College | Conflict of Interest | ImmuNext, Inc. | $100,000 - $149,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.